These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 27677233)

  • 1. [5-HT3-antagonists as a substitute for metoclopramide and domperidone: a literature review].
    Mouch I; Brouwers JR; van 't Riet E; Nieboer P; Otten MH; Jansman FG
    Ned Tijdschr Geneeskd; 2016; 160():A9887. PubMed ID: 27677233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-HT3 receptor antagonists vs traditional agents for the prophylaxis of postoperative nausea and vomiting.
    Loewen PS; Marra CA; Zed PJ
    Can J Anaesth; 2000 Oct; 47(10):1008-18. PubMed ID: 11032279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of controlled release metoclopramide and domperidone in the treatment of nausea and vomiting.
    Roy P; Patel NH; Miller AJ
    Br J Clin Pract; 1991; 45(4):247-51. PubMed ID: 1810356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
    Cunningham RS
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A network meta-analysis on the efficacy of serotonin type 3 receptor antagonists used in adults during the first 24 hours for postoperative nausea and vomiting prophylaxis.
    Tang DH; Malone DC
    Clin Ther; 2012 Feb; 34(2):282-94. PubMed ID: 22296947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RETRACTED ARTICLE: Combination Antiemetic Regimens for Prevention of Postoperative Nausea and Vomiting : Focus on High-Risk Patients.
    Fujii Y
    Clin Drug Investig; 2002 Sep; 22(9):561-574. PubMed ID: 29492850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of palonosetron in postoperative nausea and vomiting (PONV)-a meta-analysis.
    Singh PM; Borle A; Gouda D; Makkar JK; Arora MK; Trikha A; Sinha A; Goudra B
    J Clin Anesth; 2016 Nov; 34():459-82. PubMed ID: 27687434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis.
    Rojas C; Raje M; Tsukamoto T; Slusher BS
    Eur J Pharmacol; 2014 Jan; 722():26-37. PubMed ID: 24184669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlling emesis related to cancer therapy.
    Aapro MS
    Eur J Cancer; 1991; 27(3):356-61. PubMed ID: 1827331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [An outline of 5-HT3 receptor antagonists (2)--In clinical applications].
    Tsukagoshi S; Ohta J; Taguchi T
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2276-81. PubMed ID: 8259839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology and preclinical antiemetic properties of ondansetron.
    Tyers MB
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):1-8. PubMed ID: 1387245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials.
    Vrabel M
    Clin J Oncol Nurs; 2007 Dec; 11(6):809-13. PubMed ID: 18063539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
    J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
    Mahesh R; Perumal RV; Pandi PV
    Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic management of nausea and vomiting.
    Marin J; Ibañez MC; Arribas S
    Gen Pharmacol; 1990; 21(1):1-10. PubMed ID: 2404830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research.
    Sanger GJ; Andrews PLR
    Front Pharmacol; 2018; 9():913. PubMed ID: 30233361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.